It Is Too Soon for Clinical Trials on Artificial Wombs
By Vardit Ravitsky and Louise King,
Scientific American
| 06. 01. 2024
Artificial wombs are moving from the realm of science fiction to possible trials with severely premature human babies. We are excited about the great potential benefits of this technology; however, with fetal rights now a political front in the abortion debate, we believe that society must address the ethical and legal implications well before those clinical trials begin.
Globally, preterm birth is the leading cause of death in children under age five. An artificial womb could provide severely premature newborns with an environment like the uterus by suspending the fetus in a flexible container filled with lab-made amniotic fluid. This innovation—so far tested only in animals—might mitigate or even prevent complications of prematurity by allowing the fetus’s underdeveloped heart and lungs to continue to grow.
An advisory panel of the U.S Food and Drug Administration is now considering whether to permit those first in-human clinical trials, despite only limited success in animal trials. Currently, from a bioethical perspective, it is not clear that animal models provide enough evidence to move forward with human trials. However, if...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...